Financial Report: WuXi PharmaTech

WuXi PharmaTech

4Q Revenues: $88.6 million (+20%)

4Q Earnings: $17.3 million (+42%)

FY Revenues: $334.1 million (+24%)

FY Earnings: $90.8 million (+72%)

Comments: Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues. For the year, growth was driven by both China- and U.S.-based Lab Services revenue (+18%) and 95% growth in Manufacturing Services revenues. In the quarter, earnings include a 38% growth in income from continuing operations and the non-recurrence of a loss from discontinued operations in 4Q10. FY earnings include a 30% increase in operating income and a favorable change in other income (expenses).